MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by de León, J. H.
Right arrow Articles by Weber, W. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by de León, J. H.
Right arrow Articles by Weber, W. W.

Vol. 58, Issue 2, 288-299, August 2000

Characterization of Naturally Occurring and Recombinant Human N-Acetyltransferase Variants Encoded by NAT1*

Jesús H. de León,1 Kostas P. Vatsis,2 and Wendell W. Weber

Department of Pharmacology, Medical School, The University of Michigan, Ann Arbor, Michigan

The genotype at the NAT1* locus of an interethnic population of 38 unrelated subjects was determined by direct sequencing of 1.6-kb fragments amplified by PCR. The coding exon alone and together with the 3' noncoding exon of the wild-type (NAT1*4) and the three mutant alleles (NAT1*10, *11, and *16) detected was expressed in Escherichia coli and COS-1 cells, respectively, and the cytosolic fraction of mononuclear leukocytes from NAT1*4/*4 and NAT1*10/*10 homozygotes was also isolated. Recombinant and leukocyte cytosolic preparations were thoroughly characterized by N-acetylation activity with several NAT1-specific and -selective substrates, as well as by steady-state kinetics with varying amounts of the substrate (fixed acetyl CoA) and acetyl CoA (fixed substrate), thermodynamics, stability, and protein immunoreactivity with a polyclonal human anti-NAT1. The polyadenylation signal mutation in the 3' noncoding sequence of NAT1*10 affected none of the aforementioned parameters evaluated both with recombinant NAT1*10 and with the naturally occurring allele. Function was also unaffected by the coding and 3' noncoding exon mutations in NAT1*11. In contrast, the three extra adenosines located immediately after the sixth position of the polyadenylation signal in the 3' untranslated region of NAT1*16 ostensibly caused disruption of the predicted secondary structure of the pre-mRNA for NAT1 16, culminating in parallel 2-fold decreases in the amount and catalytic activity of NAT1 16 in COS-1 cell cytosol. This novel finding in N-acetylation pharmacogenetics clearly demonstrates a direct link between reduced catalytic activity and structural alteration in the 3' untranslated region of an NAT variant (NAT1*16) brought about by mutation.


1 Present address: Health Effects Laboratory Division, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, Morgantown, WV 26505-2845.

2 Present address: Department of Biological Chemistry, The University of Michigan Medical School, M5440 Medical Science Building I, Ann Arbor, MI 48109-0606.


Copyright © 2000 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
L. Jiao, M. A. Doll, D. W. Hein, M. L. Bondy, M. M. Hassan, J. E. Hixson, J. L. Abbruzzese, and D. Li
Haplotype of N-Acetyltransferase 1 and 2 and Risk of Pancreatic Cancer
Cancer Epidemiol. Biomarkers Prev., November 1, 2007; 16(11): 2379 - 2386.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
S. Fronhoffs, T. Bruning, E. Ortiz-Pallardo, P. Brode, B. Koch, V. Harth, A. Sachinidis, H. M. Bolt, C. Herberhold, H. Vetter, et al.
Real-time PCR analysis of the N-acetyltransferase NAT1 allele *3, *4, *10, *11, *14 and *17 polymorphism in squamous cell cancer of head and neck
Carcinogenesis, September 1, 2001; 22(9): 1405 - 1412.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
I. Cascorbi, I. Roots, and J. Brockmoller
Association of NAT1 and NAT2 Polymorphisms to Urinary Bladder Cancer: Significantly Reduced Risk in Subjects with NAT1*10
Cancer Res., July 1, 2001; 61(13): 5051 - 5056.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2000 by the American Society for Pharmacology and Experimental Therapeutics